Treatment for cognitive impairments in long COVID patients
DAOIB for the Treatment of Cognitive Impairment Induced by COVID-19 -An Open Trial
This study is testing whether a treatment called DAOIB can help people with long COVID who are struggling with thinking and memory problems feel better over 24 weeks.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Chang Gung Memorial Hospital Academic / other |
| Locations | 1 site (Kaohsiung City) |
| Trial ID | NCT05764538 on ClinicalTrials.gov |
What this trial studies
This is a 24-week open trial aimed at evaluating the effects of DAOIB on cognitive impairments in patients suffering from long COVID. Participants will receive DAOIB for the entire duration and will be assessed every 8 weeks to monitor improvements in cognitive function, mood symptoms, global functioning, and quality of life. The study specifically targets individuals who have experienced cognitive issues following COVID-19 infection, ensuring they meet specific health criteria. The goal is to determine the efficacy of DAOIB in alleviating these cognitive challenges.
Who should consider this trial
Good fit: Ideal candidates are individuals with post-COVID-19 cognitive impairments who are physically healthy and can effectively communicate.
Not a fit: Patients with significant cerebrovascular disease or major neurological, psychiatric, or medical conditions unrelated to long COVID may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve cognitive function and quality of life for long COVID patients experiencing brain fog.
How similar studies have performed: While there is ongoing research into cognitive impairments related to long COVID, the specific use of DAOIB in this context is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * "post-COVID-19 condition" defined by WHO (symptoms present at three months after SARS-CoV-2 infection and last for at least 2 months which cannot be explained by an alternative diagnosis)(Cabrera Martimbianco, Pacheco et al. 2021) and COVID-induced cognitive impairments * physically healthy and have all laboratory assessments (including urine/blood routine, biochemical tests, and electrocardiograph) within normal limits * have sufficient education to communicate effectively and are capable of completing the assessments of the study Exclusion Criteria: * history of significant cerebrovascular disease * Hachinski Ischemic Score \> 4 * major neurological, psychiatric or medical conditions other than long COVID-induced cognitive impairments * memantine use (memantine is an NMDAR partial antagonist) * substance (including alcohol) abuse or dependence * delusion, hallucination or delirium symptoms * severe visual or hearing loss * inability to follow the protocol
Where this trial is running
Kaohsiung City
- Kaohsiung Chang Gung Memorial Hospital — Kaohsiung City, Taiwan (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.